ArticleJournal of clinical periodontology2026
Proteome-Guided Drug Target Discovery for Periodontitis.
Article in Journal of clinical periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study.Journal of clinical periodontology · 2026Article
- Proteome-Guided Drug Target Discovery for Periodontitis.Journal of clinical periodontology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivePeriodontitis is a chronic inflammatory disease driven by immune dysfunction and microbial imbalance. This study aims to identify circulating druggable proteins causally linked to the disease. MATERIALS AND
methodsWe integrated proteomics data from deCODE genetics with periodontitis genome-wide association studies (GWAS) from the Million Veteran Program to identify proteins associated with periodontitis. Findings were replicated using GWAS data from the Gene-Lifestyle Interactions in Dental Endpoints consortium. Causal associations were validated using genetic and statistical methods, and the identified proteins were assessed for biological relevance and druggability.
resultsAmong the 2088 evaluated proteins, three showed robust evidence of causal association with periodontitis: FGF2 (fibroblast growth factor 2) (odds ratio [OR]: 1.06, 95% confidence interval [CI] 1.032-1.082), AZGP1 (zinc-alpha-2-glycoprotein) (OR: 1.12, 95% CI 1.058-1.189) and BTC (betacellulin) (OR: 0.86, 95% CI 0.789-0.942). Replication analysis confirmed associations for 18 proteins, with 16 showing high colocalisation. Further evaluation of drug target databases revealed indirect links between the identified proteins and approved therapies for inflammatory conditions, suggesting potential therapeutic relevance.
conclusionThis study identifies three circulating proteins-FGF2, AZGP1 and BTC-as causally associated with periodontitis, highlighting their potential as therapeutic targets. These results provide a foundation for future research into targeted therapies for periodontitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.